Molecular risk stratification in chronic lymphocytic leukemia

Paul Hengeveld

Molecular risk stratification in chronic lymphocytic leukemia

Paul Hengeveld

Immunology

Research output: Types of Thesis › Doctoral Thesis › Internal

118 Downloads (Pure)

Abstract

Chronic lymphocytic leukemia (CLL) is a type of blood cancer characterized by the accumulation of monoclonal, mature B cells. CLL is well known for its clinical heterogeneity: while some patients need therapy at the moment of diagnosis, others may go years or even decades without treatment. In addition, while generally responding well to treatment, the duration of remission in CLL is highly variable. In this thesis, I have used several molecular techniques to better characterize this heterogeneity, in order to achieve more accurate prognostic stratification of CLL patients before, during and after treatment.

Original language	English
Awarding Institution	Erasmus University Rotterdam
Supervisors/Advisors	Langerak, Anton W., Supervisor Levin, Mark-David, Co-supervisor Westerweel, Peter, Co-supervisor
Award date	27 Mar 2024
Place of Publication	Rotterdam
Print ISBNs	978-94-6483-677-6
Publication status	Published - 27 Mar 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

final dissertation Hengeveld, PaulFinal published version, 28.7 MB

Cite this

@phdthesis{52195bf518e84afab2b7f5fc59250fea,

title = "Molecular risk stratification in chronic lymphocytic leukemia",

abstract = "Chronic lymphocytic leukemia (CLL) is a type of blood cancer characterized by the accumulation of monoclonal, mature B cells. CLL is well known for its clinical heterogeneity: while some patients need therapy at the moment of diagnosis, others may go years or even decades without treatment. In addition, while generally responding well to treatment, the duration of remission in CLL is highly variable. In this thesis, I have used several molecular techniques to better characterize this heterogeneity, in order to achieve more accurate prognostic stratification of CLL patients before, during and after treatment.",

author = "Paul Hengeveld",

year = "2024",

month = mar,

day = "27",

language = "English",

isbn = "978-94-6483-677-6",

school = "Erasmus University Rotterdam",

}

TY - BOOK

T1 - Molecular risk stratification in chronic lymphocytic leukemia

AU - Hengeveld, Paul

PY - 2024/3/27

Y1 - 2024/3/27

N2 - Chronic lymphocytic leukemia (CLL) is a type of blood cancer characterized by the accumulation of monoclonal, mature B cells. CLL is well known for its clinical heterogeneity: while some patients need therapy at the moment of diagnosis, others may go years or even decades without treatment. In addition, while generally responding well to treatment, the duration of remission in CLL is highly variable. In this thesis, I have used several molecular techniques to better characterize this heterogeneity, in order to achieve more accurate prognostic stratification of CLL patients before, during and after treatment.

AB - Chronic lymphocytic leukemia (CLL) is a type of blood cancer characterized by the accumulation of monoclonal, mature B cells. CLL is well known for its clinical heterogeneity: while some patients need therapy at the moment of diagnosis, others may go years or even decades without treatment. In addition, while generally responding well to treatment, the duration of remission in CLL is highly variable. In this thesis, I have used several molecular techniques to better characterize this heterogeneity, in order to achieve more accurate prognostic stratification of CLL patients before, during and after treatment.

M3 - Doctoral Thesis

SN - 978-94-6483-677-6

CY - Rotterdam

ER -

Molecular risk stratification in chronic lymphocytic leukemia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this